Estrogen receptors β1 and β2 are associated with distinct responses of estrogen receptor α-positive breast carcinoma to adjuvant endocrine therapy

Cancer Letters

Volumn 358, Issue 1, 2015, Pages 37-42

  Dhimolea, Eugen ^a   Tiniakos, Dina G ^b   Chantzi, Niki I ^b   Goutas, Nikolaos ^c   Vassilaros, Stamatis D ^d   Mitsiou, Dimitra J ^a   Alexis, Michael N ^a  

^a INSTITUTE OF BIOLOGY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c Ultrasound Department   (Greece)

^d Prolipsis Breast Diagnostic Center   (Greece)

Author keywords

Breast carcinoma; Endocrine therapy; ER 1; ER 2; Immunohistochemistry

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTROGEN RECEPTOR BETA1; ESTROGEN RECEPTOR BETA2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS;

EID: 84921288851     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.12.022     Document Type: Article

References (33)

1. Patani N., Martin L.A., Dowsett M. Biomarkers for the clinical management of breast cancer: international perspective. Int. J. Cancer 2013, 133(1):1-13. 10.1002/ijc.27997.
2. Thomas C., Gustafsson J.Å. The different roles of ER subtypes in cancer biology and therapy. Nat. Rev. Cancer 2011, 11(8):597-608. 10.1038/nrc3093.
3. Moore J.T., McKee D.D., Slentz-Kesler K., Moore L.B., Jones S.A., Horne E.L., et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem. Biophys. Res. Commun 1998, 247(1):75-78. 10.1006/bbrc.1998.8738.
4. Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouchi Y., et al. Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 1998, 26(15):3505-3512. 10.1093/nar/26.15.3505.
5. Leung Y.K., Mak P., Hassan S., Ho S.M. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc. Natl. Acad. Sci. U.S.A. 2006, 103(35):13162-13167. 10.1073/pnas.0605676103.
6. Murphy L.C., Leygue E. The role of estrogen receptor-β in breast cancer. Semin. Reprod. Med 2012, 30(1):5-13. 10.1055/s-0031-1299592.
7. Powell E., Shanle E., Brinkman A., Li J., Keles S., Wisinski K.B., et al. Identification of estrogen receptor dimer selective ligands reveals growth-inhibitory effects on cells that co-express ERα and ERβ. PLoS ONE 2012, 7(2):e30993. 10.1371/journal.pone.0030993.
8. Omoto Y., Eguchi H., Yamamoto-Yamaguchi Y., Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 2003, 22(32):5011-5020. 10.1038/sj.onc.1206787.
9. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004, 64(1):423-428. 10.1158/0008-5472.CAN-03-2446.
10. Ström A., Hartman J., Foster J.S., Kietz S., Wimalasena J., Gustafsson J.A. Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101(6):1566-1571. 10.1073/pnas.0308319100.
11. Zhao C., Matthews J., Tujague M., Wan J., Ström A., Toresson G., et al. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Res 2007, 67(8):3955-3962. 10.1158/0008-5472.CAN-06-3505.
12. Honma N., Horii R., Iwase T., Saji S., Younes M., Takubo K., et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J. Clin. Oncol 2008, 26(22):3727-3734. 10.1200/JCO.2007.14.2968.
13. Nakopoulou L., Lazaris A.C., Panayotopoulou E.G., Giannopoulou I., Givalos N., Markaki S., et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J. Clin. Pathol 2004, 57(5):523-528. 10.1136/jcp.2003.008599.
14. Novelli F., Milella M., Melucci E., Di Benedetto A., Sperduti I., Perrone-Donnorso R., et al. A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008, 10(5):R74. 10.1186/bcr2139.
15. Miller W.R., Anderson T.J., Dixon J.M., Saunders P.T. Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br. J. Cancer 2006, 94(9):1333-1338. 10.1038/sj.bjc.6603082.
16. Murphy L.C., Leygue E., Niu Y., Snell L., Ho S.M., Watson P.H. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br. J. Cancer 2002, 87(12):1411-1416. 10.1038/sj.bjc.6600654.
17. O'Neill P.A., Davies M.P., Shaaban A.M., Innes H., Torevell A., Sibson D.R., et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br. J. Cancer 2004, 91(9):1694-1702. 10.1038/sj.bjc.6602183.
18. Shaaban A.M., Green A.R., Karthik S., Alizadeh Y., Hughes T.A., Harkins L., et al. Nuclear and cytoplasmic expression of ERbeta1, ERbeta2, and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin. Cancer Res 2008, 14(16):5228-5235. 10.1158/1078-0432.CCR-07-4528.
19. Yamashita H., Nishio M., Kobayashi S., Ando Y., Sugiura H., Zhang Z., et al. Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer. Breast Cancer Res 2005, 7(5):R753-R764. 10.1186/bcr1285.
20. Saji S., Omoto Y., Shimizu C., Warner M., Hayashi Y., Horiguchi S., et al. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor. Cancer Res 2002, 62(17):4849-4853.
21. Esslimani-Sahla M., Simony-Lafontaine J., Kramar A., Lavaill R., Mollevi C., Warner M., et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res 2004, 10(17):5769-5776. 10.1158/1078-0432.CCR-04-0389.
22. Mansell J., Monypenny I.J., Skene A.I., Abram P., Carpenter R., Gattuso J.M., et al. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res. Treat 2009, 117(1):91-98. 10.1007/s10549-008-0291-z.
23. Davies C., Godwin J., Gray R., Clarke M., Cutter D., et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 10.1016/S0140-6736(11)60993-8.
24. Cossetti R.J., Tyldesley S.K., Speers C.H., Zheng Y., Gelmon K.A. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J. Clin. Oncol 2014, Epub ahead of print]. JCO.2014.57.2461 [pii].
25. Chantzi N.I., Meligova A.K., Dhimolea E., Petrou C.C., Mitsiou D.J., Magafa V., et al. Insights into ectopic estrogen receptor expression, nucleocytoplasmic distribution and interaction with chromatin obtained with new antibodies to estrogen receptors α and β. Steroids 2011, 76(10-11):974-985. 10.1016/j.steroids.2011.05.010.
26. Chantzi N.I., Tiniakos D.G., Palaiologou M., Goutas N., Filippidis T., Vassilaros S.D., et al. Estrogen receptor beta 2 is associated with poor prognosis in estrogen receptor alpha-negative breast carcinoma. J. Cancer Res. Clin. Oncol 2013, 139(9):1489-1498. 10.1007/s00432-013-1467-4.
27. Chantzi N.I., Palaiologou M., Stylianidou A., Goutas N., Vassilaros S., Kourea H.P., et al. Estrogen receptor β2 is inversely correlated with Ki-67 in hyperplastic and noninvasive neoplastic breast lesions. J. Cancer Res. Clin. Oncol 2014, 140(6):1057-1066. 10.1007/s00432-014-1652-0.
28. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M., Clark G.M., et al. Reporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat 2006, 100(2):229-235. 10.1007/s10549-012-2040-6.
29. Harvey J.M., Clark G.M., Osborne C.K., Allred D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol 1999, 17(5):1474-1481.
30. Elston C.W., Ellis I.O. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19(5):403-410. 10.1046/j.1365-2559.2002.14892.x.
31. Chang E.C., Frasor J., Komm B., Katzenellenbogen B.S. Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 2006, 147(10):4831-4842. doi:. http://dx.doi.org/10.1210/en.2006-0563.
32. Frasor J., Chang E.C., Komm B., Lin C.Y., Vega V.B., Liu E.T., et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. Cancer Res 2006, 66(14):7334-7340. 10.1158/0008-5472.CAN-05-4269.
33. Rosin G., de Boniface J., Karthik G.M., Frisell J., Bergh J., Hartman J. Oestrogen receptors β1 and βcx have divergent roles in breast cancer survival and lymph node metastasis. Br. J. Cancer 2014, 111(5):918-926. 10.1038/bjc.2014.398.